BioWorld Asia

Sep. 25, 2002

KS Biomedix, Nycomed Sign Deal For TransMID 107 Cancer Therapy

LONDON - KS Biomedix Holdings plc agreed to a licensing deal worth up to US$60 million for its TransMID 107 brain cancer treatment with Nycomed Group. (BioWorld International) Read More

Neuro3d Raises EUR20M Privately To Fund Work In CNS Disorders

BCLC Says BRCA1 Increases Risk Of Other Cancers In Women

Modex, IsoTis Plan To Merge Programs In Orthopedics, Skin

EU Urges Use Of Biotechnology In And From Developing World

European Parliament Aims To Tighten GM Trade Rules

Eirx Pharma Formed Through Three-Way Anglo-Irish Merger

Cardion Closes EUR10M Financing To Fund CRB-15, Stem Cell Work

Acambis Completes Manufacture Of First Batch Of Smallpox Vaccine

Zentaris, Access Oncology Enter $30M Alliance For Cancer Drug

Other News To Note

Genset Shareholders Accept Bid From Serono; Integration Begins

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

BioWorld Science

Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...